A recent study in a cohort of 179 patients with breast cancer identified higher expression of both ABCB1 and ABCC1 as associated with shorter duration of T-DXd treatment, and ABCB1 was also associated with shorter T-DXd-specific OS30. The gene discussed is ABCC1; the disease is breast cancer.